Universal Ibogaine Inc (TSE:IBO) has released an update.
Universal Ibogaine Inc. has successfully completed a non-brokered private placement, issuing over 57 million common shares at $0.01 each, resulting in proceeds of approximately $575,576. These funds are earmarked for advancing clinical trials for ibogaine-based addiction treatment in Canada and for general corporate purposes. The company is pioneering a new addiction treatment protocol that could dramatically improve outcomes for those struggling with opioid use disorder.
For further insights into TSE:IBO stock, check out TipRanks’ Stock Analysis page.
